More than 20 years ago, RBOI founder Dr. Norman Anderson successfully treated a man whose metastatic melanoma had produced 23 brain lesions. Anderson performed whole brain radiation, administering low doses twice a day. His discovery led to a study with 19 patients, whose melanomas together had metastasized to the brain, other areas of the head, neck, lung, abdomen, liver, pelvis, and extremities, along with lymph nodes. They had all exhausted their other treatment options.

Now, over 100 melanoma patients have completed treatment. Eighty percent of people whose melanoma was metastatic at the outset are alive three years after radiation treatment, and the occurrence of further disease elsewhere has been “markedly diminished if not eliminated, increasing the potential for a cure.” Other patients have remained disease-free for up to a decade and longer.

Dr. Anderson’s radiation protocol, often used without added surgery or pharmaceuticals, eliminated melanomas that had been resistant to other procedures, or that had returned following surgery, chemotherapy, and immunotherapy.

“Dr. Anderson points out that there is a big difference between once-daily radiation and smaller doses of twice-daily radiation. More frequent radiation has eliminated tumors even in untreated areas, a historically rare phenomenon called the abscopal effect.”

Twice-daily radiation can eliminate all signs of the disease, reduce side effects significantly, and extend patient survival, for a small fraction of the cost of other treatments. According to the medical literature, treating advanced melanoma in which surgery is not an option can cost around $1.6 million to add a single year of progression-free survival. “Treatment with twice daily radiation as an alternative appears to offer optimum results,” Dr. Anderson says, “while markedly decreasing overall cost to a few percent.”

Annual melanoma deaths in the US total 8,430 and rising. Twice-daily radiation may help reverse that trend. Patented in the US and Australia, with 34 patents pending in Europe, Dr. Anderson’s treatment protocol is poised to serve “an essential therapeutic role for melanoma.”

Write a comment:

Your email address will not be published.

2025 ©
Robert Boissoneault Oncology Institute